Levothyroxine Treatment of Subclinical Hypothyroidism and the Risk of Adverse Cardiovascular Events
Thyroid® · 2024
DOI: 10.1089/thy.2024.0227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thyroid®, 2024. Verfasst von Oriana Hoi Yun Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Jewish General Hospital, Montreal, Canada. Hauptthemen laut MEDLINE: Hypothyroidism, Thyroxine, Cardiovascular Diseases, Thyrotropin. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Importance: There is uncertainty as to whether treatment of subclinical hypothyroidism (SCH) is associated with cardiovascular outcomes.
Objectives
To determine whether levothyroxine replacement therapy decreases the risk of major adverse cardiovascular events (MACE) among individuals with SCH defined as having a thyrotropin (TSH) level between 5 and 10 mU/L.
Design
We conducted a population-based cohort study using a prevalent new-user design.
Setting
The study utilized data from the United Kingdom Clinical Practice Research Datalink.
Participants
We identified a base cohort of individuals aged ≥18 years with incident SCH defined as having at least two TSH levels between 5 and 10 mU/L within one year between 1998 and 2018. We matched 76,946 levothyroxine treated to 76,946 untreated individuals based on age, sex, calendar time, duration of SCH, and time-conditional propensity score. We compared individuals with SCH treated with levothyroxine with individuals with no treatment. Exposure: Levothyroxine treatment versus no treatment. Main Outcome Measures: The primary outcome, MACE, was defined as a composite of nonfatal myocardial infarction, nonfatal ischemic stroke, and cardiovascular-related mortality.
Results
The mean age of the study cohort was 62.8 years, and 76.5% were women. During a median follow-up time of 1.6 years (interquartile range: 0.5–4.2), the incidence rate for MACE among individuals treated with levothyroxine was 12.8 per 1000 person-years; confidence interval (CI): 12.2–13.3 and 13.9 per 1000 person-years; CI: 13.4–14.3 among nontreated individuals. Levothyroxine treatment was associated with a small decreased risk of MACE (hazard ratio: 0.88; CI: 0.83–0.93).
Conclusions
Levothyroxine treatment of SCH was associated with a small decreased risk of MACE. However, given the observational nature of the study, residual confounding should be considered in the interpretation of this finding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Jewish General Hospital, Montreal, Canada.
- Department of Medicine, McGill University, Montreal, Canada.
- Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada.
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada.
- Department of Pediatrics, McGill University, Montreal, Canada.
- Department of Family Medicine, McGill University, Montreal, Canada.
ORCID-Profile: Kristian B Filion, Robert W Platt
Zitieren
APA
Yu, O. H. Y., Filliter, C., Filion, K. B., Platt, R. W., Grad, R., & Renoux, C. (2024). Levothyroxine Treatment of Subclinical Hypothyroidism and the Risk of Adverse Cardiovascular Events. Thyroid®. https://doi.org/10.1089/thy.2024.0227
Vancouver
Yu OHY, Filliter C, Filion KB, Platt RW, Grad R, Renoux C. Levothyroxine Treatment of Subclinical Hypothyroidism and the Risk of Adverse Cardiovascular Events. Thyroid®. 2024. doi:10.1089/thy.2024.0227
BibTeX
@article{Yu2024,
author = {Yu, Oriana Hoi Yun and Filliter, Christopher and Filion, Kristian B and Platt, Robert W and Grad, Roland and Renoux, Christel},
title = {Levothyroxine Treatment of Subclinical Hypothyroidism and the Risk of Adverse Cardiovascular Events},
journal = {Thyroid®},
year = {2024},
doi = {10.1089/thy.2024.0227}
}
EUVIMED